GB2605952A - Fluorescent nucleoside triphosphates - Google Patents

Fluorescent nucleoside triphosphates Download PDF

Info

Publication number
GB2605952A
GB2605952A GB2105194.1A GB202105194A GB2605952A GB 2605952 A GB2605952 A GB 2605952A GB 202105194 A GB202105194 A GB 202105194A GB 2605952 A GB2605952 A GB 2605952A
Authority
GB
United Kingdom
Prior art keywords
compound
formula
salt
rna molecule
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB2105194.1A
Other languages
English (en)
Other versions
GB202105194D0 (en
Inventor
Esbjorner Winters Elin
Wilhelmsson Marcus
Pfeiffer Pauline
Gallard Audrey
Nilsson Jesper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Labels Biotech AB
Original Assignee
Stealth Labels Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Labels Biotech AB filed Critical Stealth Labels Biotech AB
Priority to GB2105194.1A priority Critical patent/GB2605952A/en
Publication of GB202105194D0 publication Critical patent/GB202105194D0/en
Priority to US18/555,180 priority patent/US20240209016A1/en
Priority to CA3216383A priority patent/CA3216383A1/en
Priority to JP2023562564A priority patent/JP2024513957A/ja
Priority to EP22722243.7A priority patent/EP4323373A1/en
Priority to PCT/EP2022/059666 priority patent/WO2022218943A1/en
Publication of GB2605952A publication Critical patent/GB2605952A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/117—Modifications characterised by incorporating modified base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB2105194.1A 2021-04-12 2021-04-12 Fluorescent nucleoside triphosphates Withdrawn GB2605952A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GB2105194.1A GB2605952A (en) 2021-04-12 2021-04-12 Fluorescent nucleoside triphosphates
US18/555,180 US20240209016A1 (en) 2021-04-12 2022-04-11 Fluorescent nucleoside phosphates
CA3216383A CA3216383A1 (en) 2021-04-12 2022-04-11 Fluorescent nucleoside phosphates
JP2023562564A JP2024513957A (ja) 2021-04-12 2022-04-11 蛍光ヌクレオシドホスフェート
EP22722243.7A EP4323373A1 (en) 2021-04-12 2022-04-11 Fluorescent nucleoside phosphates
PCT/EP2022/059666 WO2022218943A1 (en) 2021-04-12 2022-04-11 Fluorescent nucleoside phosphates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2105194.1A GB2605952A (en) 2021-04-12 2021-04-12 Fluorescent nucleoside triphosphates

Publications (2)

Publication Number Publication Date
GB202105194D0 GB202105194D0 (en) 2021-05-26
GB2605952A true GB2605952A (en) 2022-10-26

Family

ID=75949388

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2105194.1A Withdrawn GB2605952A (en) 2021-04-12 2021-04-12 Fluorescent nucleoside triphosphates

Country Status (6)

Country Link
US (1) US20240209016A1 (https=)
EP (1) EP4323373A1 (https=)
JP (1) JP2024513957A (https=)
CA (1) CA3216383A1 (https=)
GB (1) GB2605952A (https=)
WO (1) WO2022218943A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217753B (zh) * 2023-01-04 2024-02-23 齐鲁工业大学(山东省科学院) 木聚糖粘度荧光探针的制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024144A2 (en) * 1993-04-19 1994-10-27 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5594121A (en) * 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150361124A1 (en) * 2013-01-22 2015-12-17 Universitaet Hamburg Method for the solid-phase based synthesis of phosphate-bridged nucleoside conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594121A (en) * 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
WO1994024144A2 (en) * 1993-04-19 1994-10-27 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Beilstein Journal of Organic Chemistry, Vol. 14, 2018, (Bood Mattias et al), pages 114-129, ISSN 1860-5397. *
Chemical Science, Vol 9(14), 2018, (Bood Mattias et al), pages 3494-3502, ISSN 2041-6520. *
Chemistry - A European Journal, Vol. 18(19), 2012, (Dierckx, Anke et al), pages 5987-5997, ISSN: 0947-6539. *
Journal of the American Chemical Society, Vol. 139(27), 2017, (Wranne, Moa S. et al), pages 9271-9280, ISSN: 0002-7863. *
Physical Chemistry Chemical Physics, Vol. 20(45), 2018, (Fisher, Rachel S. et al), pages 28487-28498, ISSN: 1463-9076. *
Tetrahedron Letters, Vol. 40(51), 1999, (Buhr, Chris A. et al), pages 8969-8970, ISSN: 0040-4039. *

Also Published As

Publication number Publication date
JP2024513957A (ja) 2024-03-27
EP4323373A1 (en) 2024-02-21
US20240209016A1 (en) 2024-06-27
CA3216383A1 (en) 2022-10-20
WO2022218943A1 (en) 2022-10-20
GB202105194D0 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
JP2023510778A (ja) ナノマテリアル
CA2882201C (en) Tenofovir prodrug and pharmaceutical uses thereof
Simmons et al. Mechanism-based solution to the ProTide synthesis problem: selective access to Sofosbuvir, Acelarin, and INX-08189
JPWO2007094135A1 (ja) オリゴヌクレオチド誘導体及びその利用
Zhou et al. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2′, 4′-carbocyclic-LNAs and-ENAs leads to significant modulation of antisense properties
US20240209016A1 (en) Fluorescent nucleoside phosphates
Silkenath et al. Phosphonate and thiasugar analogues of glucosamine-6-phosphate: activation of the glmS riboswitch and antibiotic activity
Takahashi et al. Synthesis of P-modified DNA from boranophosphate DNA as a precursor via acyl phosphite intermediates
EP4172170B1 (en) Fluorescent cytosine analogues and their application in transcription and translation
Kirschberg et al. Discovery of a 2′-fluoro-2′-C-methyl C-nucleotide HCV polymerase inhibitor and a phosphoramidate prodrug with favorable properties
CN121335889A (zh) 5’-修饰单体、寡核苷酸及双链rna
Fernandez et al. Effective carrier-free gene-silencing activity of sphingosine-modified siRNAs
WO2020002469A1 (en) Methods and reagents for cross-linking cellular dna and rna via strain-promoted double-click reactions
AU2012254580B2 (en) Process for preparing phosphate compound bearing isotope
Procházková et al. Could 5′-N and S ProTide analogues work as prodrugs of antiviral agents?
Sterrenberg Novel Pronucleotide Reporters for bioorthogonal Labeling of Nucleic Acids
Thillier et al. Solid-phase synthesis of 5′-triphosphate 2′-5′-oligoadenylates analogs with 3′-O-biolabile groups and their evaluation as RNase L activators and antiviral drugs
Kocisova et al. Monitoring of labeled antisense oligonucleotides within living cells by using a multifrequency phase/modulation approach for fluorescence lifetime measurements
WO2025259992A1 (en) 5'-modified monomers, oligonucleotides and double-stranded rnas
Farrow Investigations of DNA and anthracene as agents for drug release
TW202606725A (zh) ５＇－經修飾之單體、寡核苷酸及雙股ｒｎａ
Hu Design, Synthesis, and Applications of Heterocyclooctynes and Small-strained Rings: Advancing Bioorthogonal Chemistry and Dna-encoded Libraries
Juneau Introduction of Modifications to the Nucleic Acid Scaffold for the Preparation of Circular Structures and Applications in Biochemistry
Hammill The synthesis and in vivo evaluation of chemically modified siRNAs that contain red-shifted internal azobenzene derivative spacers for selective and tunable photocontrol of activity without UV light
Dutta et al. The R-diastereomer of 6′-O-toluoyl-carba-LNA modification in the core region of siRNA leads to 24-times improved RNA silencing potency against the HIV-1 compared to its S-counterpart

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: STEALTH LABELS BIOTECH AB

Free format text: FORMER OWNER: CHALMERS VENTURES AB

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)